Traditional MedicareCoverageMedium impact
MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma
Medicare/CMS - LCD·Dermatology, Oncology, Pathology·Local Coverage Determination
Effective date
May 28, 2026
We identified it
Jun 17, 2026
Summary
Medicare has established a new Local Coverage Determination for molecular biomarker testing used to assess risk in cutaneous squamous cell carcinoma (skin cancer). This policy will define coverage criteria and billing requirements for genetic testing that helps determine cancer progression risk.
Action Required
Before May 28, 2026: Billing team must review the full LCD L39614 policy details to understand coverage criteria for molecular biomarker testing in cutaneous squamous cell carcinoma cases. Providers treating skin cancer patients should be notified of new testing coverage guidelines. Update prior authorization workflows if molecular biomarker tests require pre-approval under this LCD.